Catalent's biologic unit has been manufacturing large-molecule drugs at a plant in Middleton, WI, for some time. But seeing the big run-up in development of new biologic medicines, the contract manufacturer decided it needed more capacity--four times more. So Catalent Biologics went down the road and built a 100,000-square-foot plant in Madison, WI, designed around single-use capabilities. The new facility has cGMP production, from 10 liters to 1,000 liters and non-GMP production up to 250 liters, to provide flexible GMP production of multiple cell lines. The company will move the 89 employees from the old plant to the new facility, where it expects to employ more than 100 people. To further its place in biologics, Catalent this month also said it had licensed Redwood Bioscience's antibody drug conjugate platform for use in delivering toxic therapies for cancer treatments. Release | More